CryoPort, Inc. 10-Q Summary
Business Context and Reporting Period
Company: CryoPort, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: CryoPort provides innovative cold chain frozen shipping solutions, specifically reusable dry vapor cryogenic shippers and a web-based tracking portal for high-value, temperature-sensitive biological and pharmaceutical materials. The company recently shifted its business model from selling shippers to a per-use leasing model with value-added services. A strategic agreement with FedEx was signed in January 2010 to lease shippers for FedEx customers.
Key Financial Metrics
| Metric | Q2 2010 (Three Months Ended June 30) | Q2 2009 (Three Months Ended June 30) |
|---|---|---|
| Revenues | $151,460 | $13,703 |
| Cost of Revenues | $394,535 | $149,177 |
| Gross Loss | $(243,075) | $(135,474) |
| Operating Expenses (SG&A + R&D) | $1,065,386 | $816,034 |
| Net Loss | $(1,328,804) | $(349,723) |
| Net Loss Per Share (Basic & Diluted) | $(0.16) | $(0.08) |
| Cash and Cash Equivalents (End of Period) | $2,097,202 | $556,922 |
| Working Capital | $593,908 | Not explicitly stated (Calculated: ~$1.99M at Mar 31, 2010) |
| Total Liabilities | $5,470,950 | N/A |
| Stockholders' Deficit | $(2,067,313) | N/A |
Cash Flow Highlights (Q2 2010):
- Net cash used in operating activities: $(1,247,452)
- Net cash used in investing activities: $(255,232)
- Net cash used in financing activities: $(30,000)
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased by 1,005% ($137,757) compared to the prior year quarter, driven by the new per-use leasing business model and value-added services.
- Increased Losses: Net loss increased by 279% to $1.33 million. This was primarily due to increased operating expenses (SG&A up $214,956; R&D up $34,396) and a significant decrease in non-cash gains from derivative liabilities.
- Derivative Liability Gain: The gain on the change in fair value of derivative liabilities dropped from $3.13 million in Q2 2009 to $116,528 in Q2 2010. This reduction in non-cash income significantly impacted the net loss.
- Interest Expense: Interest expense decreased significantly from $2.53 million in Q2 2009 to $138,708 in Q2 2010, largely due to the amortization of debt discount in the prior year.
- Customer Concentration: In Q2 2010, CDx Holdings, Inc. accounted for 63% of total revenues, and BD Biosciences accounted for 13%. No significant concentrations existed in Q2 2009.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states substantial doubt about the Company's ability to continue as a going concern. Management estimates that cash on hand as of June 30, 2010, plus proceeds from a subsequent private placement, will only fund operations into the third quarter of fiscal 2011. Additional capital is required for sustained operations.
- Subsequent Financing: On August 20, 2010, the Company completed a private placement raising approximately $2.95 million in net cash proceeds (gross proceeds of $3.2 million) through the issuance of 4.57 million shares and warrants.
- Debt Obligations: The Company has significant convertible debentures ($2.62 million net) and related party notes ($1.46 million long-term, $150k current). The Company missed required payments on related party notes in April, May, and June 2010 but is within a 120-day grace period.
- Unusual Items: The financial results are heavily influenced by non-cash items, specifically the fair value adjustments of derivative liabilities (warrants and embedded conversion features) and the amortization of debt discounts.
- Outlook: Management plans to obtain additional capital through equity and debt funding but notes no assurance that such capital will be available on acceptable terms.
Key Facts for Investor Verification
- Liquidity Runway: Verify the sufficiency of the $2.95 million raised in August 2010 to extend operations beyond Q3 fiscal 2011, given the high burn rate (~$1.25M cash used in operations per quarter).
- Revenue Concentration: Assess the risk associated with CDx Holdings, Inc. representing 63% of Q2 2010 revenues.
- Debt Default Status: Confirm the status of the related party notes payable, which were in default as of June 30, 2010, though payments were made in July 2010.
- Derivative Liability Volatility: Monitor the fair value of derivative liabilities ($217,835), as fluctuations in stock price can create significant non-cash gains or losses that obscure operating performance.
- Capital Expenditures: Review the $210,851 spent on property and equipment in Q2 2010 to ensure alignment with the commercialization strategy.